HCA vs UHS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

HCA is the larger of the two ($98.80B market cap): the incumbent the market prices for continued execution (15.12x forward earnings, beta 1.10). UHS is the smaller challenger ($10.32B), cheaper on forward earnings (7.77x): more room to run, but more to prove. If you believe HCA earns its premium (15.12x forward earnings, so the market expects more from it), HCA fits. If you believe in paying less for profit, UHS fits at 7.77x.

HCA vs UHS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricHCAUHSWhat it tells you
Market cap$98.80B$10.32BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E15.127.77Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E15.697.49Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.101.11Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range59% of range37% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Reading it: UHS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how HCA and UHS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HCA and UHS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HCA and UHS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does HCA Healthcare (HCA) do?

HCA Healthcare is the largest for-profit hospital system in the United States, operating a network of acute-care hospitals alongside surgery centers, urgent-care clinics, freestanding emergency rooms, and physician clinics. Its strategy centers on building dense local networks in growing Sun Belt and suburban markets, where controlling a large share of care lets it negotiate better rates with commercial insurers, recruit physicians, and spread fixed costs. In the first quarter of 2026 HCA reported revenue of about $19.1 billion, up roughly 4% year over year, with net income near $1.6 billion and diluted EPS of about $7.15, and it reaffirmed full-year 2026 guidance of roughly $76.5 billion to $80.0 billion in revenue and $15.55 billion to $16.45 billion in adjusted EBITDA. The second quarter, ended June 30, was stronger: revenue of about $20.2 billion, up roughly 9%, net income near $1.7 billion and EPS of $7.59 against a $7.50 estimate. The third quarter, ended September 30, brought revenue of about $19.9 billion, up roughly 3.6% and above the roughly $19.3 billion expected, net income near $1.6 billion and EPS of $7.22, well ahead of the $6.63 estimate and the fifth straight beat. Trailing twelve-month revenue now stands near $78.7 billion, with net income of about $6.8 billion.

Full HCA guide

What does Universal Health Services (UHS) do?

Universal Health Services is a Pennsylvania-based healthcare company that owns and operates acute care hospitals, behavioral health facilities, outpatient centers, and ambulatory surgery locations across the United States and in the United Kingdom. Its two core segments are acute care, which covers general hospitals and emergency and surgical services, and behavioral health, which spans inpatient psychiatric and addiction treatment facilities where UHS is one of the largest operators in the country. The company also expanded its virtual behavioral health reach through the acquisition of Talkspace, and in November 2026 coverage focused on its growing outpatient behavioral health footprint.

Full UHS guide

HCA vs UHS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • HCA drivers: Scale and local-market density; Outpatient and ambulatory expansion.
  • UHS drivers: Behavioral health scale; Acute care volumes and pricing.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is reimbursement and health-care policy. For UHS, the largest risks are tied to government reimbursement.

HCA or UHS: which should you pick?

If the story you believe is HCA's (Scale and local-market density), HCA is the more direct way to own it; if it is UHS's (Behavioral health scale), UHS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HCA and UHS guides.

HCA vs UHS: the full fundamentals

HCA. At about $473 on November 20, 2026, HCA trades near 15.7x trailing and 15.1x forward earnings and under 10x EV/EBITDA, the multiple of a steady, cash-generative operator more than a high-growth stock, so it reflects reimbursement stability and buyback-driven per-share growth more than rapid revenue expansion. Analysts expect 2026 EPS of about $30.09 rising to about $31.29 in 2027, roughly 4% growth. The biggest variable is still policy: the 2026 guidance bakes in an ACA-subsidy and Medicaid hit that management is partly offsetting, and the 2027 outlook that usually arrives with the January report will show how much of it carries over.

UHS. UHS trades at about 7.5 times trailing earnings and roughly 6.1 times EV/EBITDA, well below broader market averages, with a price-to-sales ratio near 0.56. The discount reflects caution around reimbursement and policy exposure and flat expected earnings for 2027, since revenue is still growing about 5 percent a year. The 17 covering analysts have a mean target near $197, and in November 2026 RBC raised its target to $207 and Mizuho to $225.

Headline figures (approximate, November 2026): HCA shows revenue (ttm) ~$78.7 billion; Q3 2026 ~$19.9 billion, up ~3.6% year over year, net income (ttm) ~$6.8 billion, ~8.6% net margin, q3 2026 eps vs estimate $7.22 vs $6.63, full-year 2026 guidance (given with q1) Revenue ~$76.5 billion to $80.0 billion; adjusted EBITDA ~$15.55 billion to $16.45 billion; UHS shows revenue (ttm) ~$18.35B (Q3 2026 up ~5.3% YoY), net income (ttm) ~$1.46B (profit margin ~8.0%), eps (ttm) ~$23.89, q3 2026 Revenue ~$4.73B, EPS ~$5.22 vs ~$5.15 est..

The bottom line: HCA vs UHS

HCA and UHS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined HCA and UHS exposure against your real portfolio. It is not an investment adviser.

Wondering how HCA or UHS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about HCA Healthcare

Ask Walnut's AI anything about HCA and see how it fits what you own.

FAQ

What is the difference between HCA and UHS?

+

HCA Healthcare is the largest for-profit hospital system in the United States, operating a network of acute-care hospitals alongside surgery centers, urgent-care clinics, freestanding emergency rooms, and physician clinics. Universal Health Services is a Pennsylvania-based healthcare company that owns and operates acute care hospitals, behavioral health facilities, outpatient centers, and ambulatory surgery locations across the United States and in the United Kingdom. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is HCA or UHS the better stock?

+

Neither is universally better. HCA is the larger incumbent; UHS is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, HCA or UHS?

+

On forward P/E (as of November 2026), HCA trades at 15.12x and UHS at 7.77x, so UHS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both HCA and UHS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of HCA vs UHS?

+

HCA: The dominant risk is reimbursement and health-care policy. HCA depends on a mix of commercial, Medicare, and Medicaid payers, and the expiration of enhanced ACA marketplace subsidies plus Medicaid payment changes could pressure adjusted EBITDA by several hundred million dollars, with more uninsured and self-pay patients raising bad-debt and charity-care costs. Labor is a structural cost pressure: nursing and physician wages, contract-labor use, and staffing shortages can compress margins quickly. Supply, drug, and equipment costs, including exposure to tariffs and supply-chain disruption, add further cost volatility. HCA also carries substantial debt from years of buybacks, about $52.4 billion against roughly $1.0 billion of cash as of September 2026, so higher interest rates raise financing costs. Revenue growth slowed to about 3.6% in the third quarter from about 9% in the second, and analysts model only about 3% revenue growth in 2027, so per-share gains lean increasingly on buybacks and cost control. Litigation, regulatory scrutiny of billing and pricing practices, and local competition from nonprofit systems and physician-owned outpatient centers round out the risk set. UHS: The largest risks are tied to government reimbursement. A meaningful share of UHS revenue comes from Medicare and Medicaid, so changes to those programs, state Medicaid supplemental payment structures, or federal healthcare policy can move earnings materially. Reporting in November 2026 pointed to lower Medicaid supplemental payments in 2027. Labor costs, including nursing wages and contract labor, remain a swing factor for margins. The behavioral health segment carries regulatory, staffing, and reputational scrutiny given the nature of inpatient psychiatric care. Rising interest expense on debt and integration risk from acquisitions such as Talkspace add further uncertainty. Analysts expect fourth-quarter EPS of about $5.61, down roughly 4.7 percent from a year earlier, and full-year 2027 EPS of about $23.03, only slightly above 2026. Free cash flow of about $745 million over the trailing year was about half of net income, and debt stood near $6.2 billion against about $169 million of cash.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HCA or UHS; figures are approximate and dated (as of November 2026). Verify current data before investing.